Why Perfect B Is Evaluating AOD 9604: Our Clinical Perspective We began our internal evaluation of AOD 9604 in response to a consistent pattern we were seeing with patients in our South Florida practice: people who had experienced meaningful fat loss on GLP-1 medications, then plateaued or discontinued due to side effects, and were looking for a next option
By creating distinct brands, Novo Nordisk could market one specifically to diabetes patients and another to people seeking weight loss
Short course (6 to 12 months) This option may work best for people with smaller weight-loss goals, those who cant tolerate side effects, or those limited by cost or access
Some users also experience sulfur burps , a particularly unpleasant but generally harmless effect of delayed gastric emptying
Lack of Physical Activity Without movement, weight loss looks flat
They may also prescribe you some over-the-counter medications